Boston Scientific Balances Strong Q1 With Softer Outlook

Boston Scientific ((BSX)) has held its Q1 earnings call. Read on for the main highlights of the call.

Boston Scientific’s latest earnings call painted a nuanced picture of strength and strain. Management highlighted a robust first quarter, with revenue and EPS at or above guidance and several flagship franchises gaining momentum worldwide. At the same time, executives openly acknowledged mounting headwinds in urology, electrophysiology margins, and certain legacy businesses, tempering expectations for the rest of 2026.

Revenue Beat Underscores Solid Q1 Momentum

Boston Scientific reported Q1 revenue of $5.203 billion, up 11.6% year on year and ahead of guidance on an organic basis. Operational and organic growth came in at 9.4%, topping the company’s 8.5% to 10% range and showing broad demand despite pockets of weakness in specific franchises.

EPS at High End with Strong Operating Margin

Adjusted EPS reached $0.80, a 6% increase and landing at the high end of the $0.78 to $0.80 guidance band. The company delivered an adjusted operating margin of about 28.8%, reflecting disciplined cost control even as gross margin pressure from tariffs and product actions began to show.

U.S. and Asia Pacific Lead Regional Performance

The United States remained a growth engine with 11% organic expansion and double‑digit gains in five of eight business units. Asia Pacific posted 12% operational growth, aided by particularly strong trends in Japan and China that helped offset softer contributions from more challenged categories.

EP and PFA Franchise Maintains Strong Momentum

Global electrophysiology sales climbed 22% organically, including 18% growth in the U.S. and 30% internationally. Management cited rapid adoption of FARAPULSE and expansion of the OPAL mapping platform and reiterated plans for continued EP investment and next‑generation PFA catheter launches to defend its leadership.

WATCHMAN Bolstered by CHAMPION Trial Data

The WATCHMAN left atrial appendage closure franchise received a major boost from the CHAMPION trial, which met both primary and secondary endpoints. WATCHMAN grew 19% organically in Q1, and leadership now expects global full‑year growth in the mid‑teens as physicians digest the new safety and efficacy evidence.

Broader Portfolio Strength in Oncology and Endoscopy

Interventional Oncology delivered 15% organic growth, underlining its role as a key long‑term driver. Endoscopy grew 7%, supported by continued ramp of the AXIOS platform, while cardiovascular and ICVT businesses posted double‑digit gains and secured important approvals such as DCB de novo clearance in Japan and OPAL HDx in China.

Capital Returns and M&A Firepower Remain Intact

The board expanded share repurchase authorization by $4 billion, taking the total to $5 billion, with roughly $2 billion earmarked for execution in Q2. With $1.453 billion of cash on hand and expected free cash flow of about $4 billion this year, the company also reaffirmed its plan to close the Penumbra acquisition in the second half of 2026 while keeping it outside current guidance.

Guidance Cut Signals a More Cautious 2026

Management lowered Q2 organic revenue growth guidance to 5% to 7% and trimmed full‑year 2026 organic growth to 6.5% to 8.0%. The company still targets full‑year adjusted EPS of $3.34 to $3.41, up 9% to 11% from 2025 with modest operating margin expansion, but acknowledged that near‑term growth expectations have reset lower.

Urology Becomes a Clear Soft Spot

Urology grew only 1% organically in Q1, dragged down by weakness in stone management and sacral neuromodulation. Executives now see full‑year urology growth stuck in the low‑ to mid‑single‑digit range, a notable comedown from prior expectations and a key driver of the company’s more guarded outlook.

EP Outlook Tempered by Competitive Pressures

Despite strong recent EP results, the company now expects the global EP business to grow around 10% in 2026, with U.S. growth only in the mid‑single digits. Management cited higher‑than‑anticipated competitive intensity and some share erosion, signaling that the EP landscape may be tougher than previously assumed.

WATCHMAN Volumes Shift Toward Concomitant Use

WATCHMAN’s 19% organic growth still fell short of internal expectations as U.S. stand‑alone procedure volumes softened in the quarter. Management pointed to procedure prioritization, reimbursement dynamics, and a shift toward concomitant procedures as drivers, suggesting growth will rely more on integrated usage than pure stand‑alone volume.

Margin Pressure from Tariffs and Product Actions

Adjusted gross margin slipped 100 basis points to 70.5% due to tariffs and inventory charges tied to product discontinuations, even as operating margin stayed strong. Executives now expect full‑year adjusted gross margin to land slightly below 2025 levels, implying ongoing cost headwinds that will require tight expense management.

Product Discontinuations Weigh on Europe

The accelerated discontinuation of the POLARx cryo system after safety events triggered inventory charges and hurt results in Europe, the Middle East, and Africa. Regional sales comparisons were also pressured by the separate discontinuation of the ACURATE valve, compounding the drag from these portfolio rationalization moves.

CRM Weakness and Operational Constraints Persist

Cardiac Rhythm Management revenue fell 3% in Q1, underscoring ongoing challenges in that legacy franchise. While AXIOS helped offset issues, the endoscopy business continued to face temporary supply‑chain disruptions, and management warned that the second quarter is likely to be the most operationally challenging period of the year.

Guidance Highlights Growth with Notable Headwinds

For Q2, Boston Scientific now projects reported revenue growth of 5.5% to 7.5% and adjusted EPS of $0.82 to $0.84, while full‑year revenue is expected to rise 7.0% to 8.5% with 6.5% to 8.0% organic growth. The company still forecasts $3.34 to $3.41 in adjusted EPS, 50 to 75 basis points of operating margin expansion, and around $4 billion of free cash flow, signaling confidence in earnings and cash generation despite softer topline assumptions.

Boston Scientific’s earnings call balanced impressive Q1 execution against a more sober view of the year ahead. High‑growth platforms in EP, structural heart, and oncology remain firm pillars, and capital returns are set to accelerate, yet weaker urology, legacy CRM pressure, and margin headwinds temper the story. For investors, the message is one of resilient fundamentals navigating a tougher near‑term operating backdrop.